Hong Kong Stock Movement: VENUS MEDTECH-B (02500) Surges Over 14% as CARDIOVALVE TTVR Completes All Clinical Enrollment

Stock News

Oct 27

VENUS MEDTECH-B (02500) has seen a significant rise of over 14%, reporting a gain of 14.01% to HK$2.93, with a trading volume of HK$10.77 million as of the time of this report. The company announced that the Cardiovalve transcatheter tricuspid valve replacement (TTVR) confirmatory clinical study has successfully completed the enrollment of all 150 patients. This marks a major advancement in Cardiovalve's development in treating tricuspid regurgitation, signaling a key milestone towards obtaining the CE Mark. Additionally, the mid-term results of the TARGET study will be officially announced at the PCR London Valves 2025 conference this year. The company stated that it will continue to advance clinical research, registration, and commercialization efforts for various innovative products, including Cardiovalve, on a global scale, aiming to establish a comprehensive lineup of "four valves in one" structural heart valve products, providing leading solutions for valve diseases to more patients worldwide while further deepening its international development strategy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1122094206"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1122094206\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1122094206?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-27 10:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122094206","market":"sh","top_or_hot":-1,"title":"Hong Kong Stock Movement: VENUS MEDTECH-B (02500) Surges Over 14% as CARDIOVALVE TTVR Completes All Clinical Enrollment","media":"Stock News","content":"<p>VENUS MEDTECH-B (02500) has seen a significant rise of over 14%, reporting a gain of 14.01% to HK$2.93, with a trading volume of HK$10.77 million as of the time of this report. The company announced that the Cardiovalve transcatheter tricuspid valve replacement (TTVR) confirmatory clinical study has successfully completed the enrollment of all 150 patients. This marks a major advancement in Cardiovalve's development in treating tricuspid regurgitation, signaling a key milestone towards obtaining the CE Mark. Additionally, the mid-term results of the TARGET study will be officially announced at the PCR London Valves 2025 conference this year. The company stated that it will continue to advance clinical research, registration, and commercialization efforts for various innovative products, including Cardiovalve, on a global scale, aiming to establish a comprehensive lineup of \"four valves in one\" structural heart valve products, providing leading solutions for valve diseases to more patients worldwide while further deepening its international development strategy.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Movement: VENUS MEDTECH-B (02500) Surges Over 14% as CARDIOVALVE TTVR Completes All Clinical Enrollment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Movement: VENUS MEDTECH-B (02500) Surges Over 14% as CARDIOVALVE TTVR Completes All Clinical Enrollment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-27 10:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VENUS MEDTECH-B (02500) has seen a significant rise of over 14%, reporting a gain of 14.01% to HK$2.93, with a trading volume of HK$10.77 million as of the time of this report. The company announced that the Cardiovalve transcatheter tricuspid valve replacement (TTVR) confirmatory clinical study has successfully completed the enrollment of all 150 patients. This marks a major advancement in Cardiovalve's development in treating tricuspid regurgitation, signaling a key milestone towards obtaining the CE Mark. Additionally, the mid-term results of the TARGET study will be officially announced at the PCR London Valves 2025 conference this year. The company stated that it will continue to advance clinical research, registration, and commercialization efforts for various innovative products, including Cardiovalve, on a global scale, aiming to establish a comprehensive lineup of \"four valves in one\" structural heart valve products, providing leading solutions for valve diseases to more patients worldwide while further deepening its international development strategy.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02500","symbol_name":"启明医疗-B","start_time":0,"source_url":"","article_id":"1122094206","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122094206","pubTimestamp":1761531025,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"VENUS MEDTECH-B (02500) has seen a significant rise of over 14%, reporting a gain of 14.01% to HK$2.93, with a trading volume of HK$10.77 million as of the time of this report. The company announced...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02500":"启明医疗-B","BK1100":"医疗保健设备","BK1574":"生物医药B类股","BK1583":"高瓴概念"},"translate_title":"港股走势：启辰医疗-B(02500)大涨超14%，因CARDIOVALVE TTVR完成全部临床入组","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02500":1},"content_text":"VENUS MEDTECH-B (02500) has seen a significant rise of over 14%, reporting a gain of 14.01% to HK$2.93, with a trading volume of HK$10.77 million as of the time of this report. The company announced that the Cardiovalve transcatheter tricuspid valve replacement (TTVR) confirmatory clinical study has successfully completed the enrollment of all 150 patients. This marks a major advancement in Cardiovalve's development in treating tricuspid regurgitation, signaling a key milestone towards obtaining the CE Mark. Additionally, the mid-term results of the TARGET study will be officially announced at the PCR London Valves 2025 conference this year. The company stated that it will continue to advance clinical research, registration, and commercialization efforts for various innovative products, including Cardiovalve, on a global scale, aiming to establish a comprehensive lineup of \"four valves in one\" structural heart valve products, providing leading solutions for valve diseases to more patients worldwide while further deepening its international development strategy.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}